Plerixafor in the treatment of progenitor cell mobilization failure: First experience in Algeria

Hematol Oncol Stem Cell Ther. 2015 Jun;8(2):93-4. doi: 10.1016/j.hemonc.2014.11.007. Epub 2014 Dec 27.

Authors

M A Bekadja¹, R Bouhass², S Osmani², M Brahimi², S Talhi², N Yafour², A Arabi²

Affiliations

¹ Hematology and Cell Therapy Department, Etablissement Hospitalier et Universitaire 1er Novembre, University of Oran, Algeria. Electronic address: mabekadja@yahoo.fr.
² Hematology and Cell Therapy Department, Etablissement Hospitalier et Universitaire 1er Novembre, University of Oran, Algeria.

PMID: 25571787
DOI: 10.1016/j.hemonc.2014.11.007

No abstract available

Publication types

Letter

MeSH terms

Adult
Algeria / epidemiology
Antigens, CD34 / analysis
Benzylamines
Cyclams
Female
Hematopoietic Stem Cell Mobilization / methods*
Heterocyclic Compounds / therapeutic use*
Hodgkin Disease / epidemiology
Hodgkin Disease / therapy*
Humans
Lymphoma, Non-Hodgkin / epidemiology
Lymphoma, Non-Hodgkin / therapy*
Male
Middle Aged
Multiple Myeloma / epidemiology
Multiple Myeloma / therapy*
Receptors, CXCR4 / antagonists & inhibitors
Stem Cell Transplantation / methods
Young Adult

Substances

Antigens, CD34
Benzylamines
Cyclams
Heterocyclic Compounds
Receptors, CXCR4
plerixafor